Literature DB >> 33367843

Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy.

Jamie M Walker1,2, Timothy E Richardson1,2,3, Kurt Farrell4,5,6, Megan A Iida4,5,6, Chan Foong7, Ping Shang7, Johannes Attems8, Gai Ayalon9, Thomas G Beach10, Eileen H Bigio11, Andrew Budson12, Nigel J Cairns13, María Corrada14, Etty Cortes4, Dennis W Dickson15, Peter Fischer16, Margaret E Flanagan11, Erin Franklin13, Marla Gearing17, Jonathan Glass17, Lawrence A Hansen18, Vahram Haroutunian19, Patrick R Hof4,5,6, Lawrence Honig20, Claudia Kawas14, C Dirk Keene21, Julia Kofler22, Gabor G Kovacs16, Edward B Lee23, Mirjam I Lutz24, Qinwen Mao10, Eliezer Masliah18, Ann C McKee12, Corey T McMillan25, M Marsel Mesulam11, Melissa Murray15, Peter T Nelson26, Richard Perrin13, Thao Pham27, Wayne Poon14, Dushyant P Purohit4, Robert A Rissman18, Kenji Sakai28, Mary Sano19, Julie A Schneider29, Thor D Stein12, Andrew F Teich30, John Q Trojanowski23, Juan C Troncoso31, Jean-Paul Vonsattel30, Sandra Weintraub11, David A Wolk25, Randall L Woltjer27, Masahito Yamada28, Lei Yu29, Charles L White7, John F Crary4,5,6.   

Abstract

Primary age-related tauopathy (PART) is a neurodegenerative entity defined as Alzheimer-type neurofibrillary degeneration primarily affecting the medial temporal lobe with minimal to absent amyloid-β (Aβ) plaque deposition. The extent to which PART can be differentiated pathoanatomically from Alzheimer disease (AD) is unclear. Here, we examined the regional distribution of tau pathology in a large cohort of postmortem brains (n = 914). We found an early vulnerability of the CA2 subregion of the hippocampus to neurofibrillary degeneration in PART, and semiquantitative assessment of neurofibrillary degeneration in CA2 was significantly greater than in CA1 in PART. In contrast, subjects harboring intermediate-to-high AD neuropathologic change (ADNC) displayed relative sparing of CA2 until later stages of their disease course. In addition, the CA2/CA1 ratio of neurofibrillary degeneration in PART was significantly higher than in subjects with intermediate-to-high ADNC burden. Furthermore, the distribution of tau pathology in PART diverges from the Braak NFT staging system and Braak stage does not correlate with cognitive function in PART as it does in individuals with intermediate-to-high ADNC. These findings highlight the need for a better understanding of the contribution of PART to cognitive impairment and how neurofibrillary degeneration interacts with Aβ pathology in AD and PART.
© 2020 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; CA2; Cognitive status; Cornu ammonis; Hippocampal subfields; Neurodegenerative disease; Primary age-related tauopathy

Mesh:

Substances:

Year:  2021        PMID: 33367843      PMCID: PMC8453611          DOI: 10.1093/jnen/nlaa153

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.148


  41 in total

1.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

2.  The pathological process underlying Alzheimer's disease in individuals under thirty.

Authors:  Heiko Braak; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2010-12-15       Impact factor: 17.088

Review 3.  The neuropathology of chronic traumatic encephalopathy.

Authors:  Ann C McKee; Thor D Stein; Patrick T Kiernan; Victor E Alvarez
Journal:  Brain Pathol       Date:  2015-05       Impact factor: 6.508

Review 4.  Functional anatomy of human hippocampal formation and related structures.

Authors:  H Braak; E Braak; D Yilmazer; J Bohl
Journal:  J Child Neurol       Date:  1996-07       Impact factor: 1.987

5.  Are cases with tau pathology occurring in the absence of Aβ deposits part of the AD-related pathological process?

Authors:  Heiko Braak; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2014-10-31       Impact factor: 17.088

6.  Hippocampal sclerosis in dementia, epilepsy, and ischemic injury: differential vulnerability of hippocampal subfields.

Authors:  Kimmo J Hatanpaa; Jack M Raisanen; Emily Herndon; Dennis K Burns; Chan Foong; Amyn A Habib; Charles L White
Journal:  J Neuropathol Exp Neurol       Date:  2014-02       Impact factor: 3.685

7.  PART, a distinct tauopathy, different from classical sporadic Alzheimer disease.

Authors:  Kurt A Jellinger; Irina Alafuzoff; Johannes Attems; Thomas G Beach; Nigel J Cairns; John F Crary; Dennis W Dickson; Patrick R Hof; Bradley T Hyman; Clifford R Jack; Gregory A Jicha; David S Knopman; Gabor G Kovacs; Ian R Mackenzie; Eliezer Masliah; Thomas J Montine; Peter T Nelson; Frederick Schmitt; Julie A Schneider; Albert Serrano-Pozo; Dietmar R Thal; Jonathan B Toledo; John Q Trojanowski; Juan C Troncoso; Jean Paul Vonsattel; Thomas Wisniewski
Journal:  Acta Neuropathol       Date:  2015-03-17       Impact factor: 17.088

8.  Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease.

Authors:  K A Jellinger; J Attems
Journal:  Acta Neuropathol       Date:  2006-11-07       Impact factor: 17.088

9.  Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study.

Authors:  M J Ball
Journal:  Acta Neuropathol       Date:  1977-02-28       Impact factor: 17.088

10.  PART is part of Alzheimer disease.

Authors:  Charles Duyckaerts; Heiko Braak; Jean-Pierre Brion; Luc Buée; Kelly Del Tredici; Michel Goedert; Glenda Halliday; Manuela Neumann; Maria Grazia Spillantini; Markus Tolnay; Toshiki Uchihara
Journal:  Acta Neuropathol       Date:  2015-01-28       Impact factor: 17.088

View more
  15 in total

1.  Neocortical Neurofibrillary Degeneration in Primary Age-Related Tauopathy.

Authors:  Jamie M Walker; Charles L White; Kurt Farrell; John F Crary; Timothy E Richardson
Journal:  J Neuropathol Exp Neurol       Date:  2022-01-29       Impact factor: 3.685

Review 2.  Recent update on the heterogeneity of the Alzheimer's disease spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-12-17       Impact factor: 3.575

3.  Differential Vulnerability of Hippocampal Subfields in Primary Age-Related Tauopathy and Chronic Traumatic Encephalopathy.

Authors:  Kurt Farrell; Megan A Iida; Jonathan D Cherry; Alicia Casella; Thor D Stein; Kevin F Bieniek; Jamie M Walker; Timothy E Richardson; Charles L White; Victor E Alvarez; Bertrand R Huber; Dennis W Dickson; Ricardo Insausti; Kristen Dams-O'Connor; Ann C McKee; John F Crary
Journal:  J Neuropathol Exp Neurol       Date:  2022-09-19       Impact factor: 3.148

4.  TDP-43 Pathology Exacerbates Cognitive Decline in Primary Age-Related Tauopathy.

Authors:  Denis S Smirnov; David P Salmon; Douglas Galasko; Steven D Edland; Donald P Pizzo; Vanessa Goodwill; Annie Hiniker
Journal:  Ann Neurol       Date:  2022-07-11       Impact factor: 11.274

5.  The Frequency of Cerebral Amyloid Angiopathy in Primary Age-Related Tauopathy.

Authors:  Jamie M Walker; Timothy E Richardson; Kurt Farrell; Charles L White Iii; John F Crary
Journal:  J Neuropathol Exp Neurol       Date:  2022-02-24       Impact factor: 3.148

6.  Genome-wide association study and functional validation implicates JADE1 in tauopathy.

Authors:  Kurt Farrell; SoongHo Kim; Natalia Han; Megan A Iida; Elias M Gonzalez; Marcos Otero-Garcia; Jamie M Walker; Timothy E Richardson; Alan E Renton; Shea J Andrews; Brian Fulton-Howard; Jack Humphrey; Ricardo A Vialle; Kathryn R Bowles; Katia de Paiva Lopes; Kristen Whitney; Diana K Dangoor; Hadley Walsh; Edoardo Marcora; Marco M Hefti; Alicia Casella; Cheick T Sissoko; Manav Kapoor; Gloriia Novikova; Evan Udine; Garrett Wong; Weijing Tang; Tushar Bhangale; Julie Hunkapiller; Gai Ayalon; Robert R Graham; Jonathan D Cherry; Etty P Cortes; Valeriy Y Borukov; Ann C McKee; Thor D Stein; Jean-Paul Vonsattel; Andy F Teich; Marla Gearing; Jonathan Glass; Juan C Troncoso; Matthew P Frosch; Bradley T Hyman; Dennis W Dickson; Melissa E Murray; Johannes Attems; Margaret E Flanagan; Qinwen Mao; M-Marsel Mesulam; Sandra Weintraub; Randy L Woltjer; Thao Pham; Julia Kofler; Julie A Schneider; Lei Yu; Dushyant P Purohit; Vahram Haroutunian; Patrick R Hof; Sam Gandy; Mary Sano; Thomas G Beach; Wayne Poon; Claudia H Kawas; María M Corrada; Robert A Rissman; Jeff Metcalf; Sara Shuldberg; Bahar Salehi; Peter T Nelson; John Q Trojanowski; Edward B Lee; David A Wolk; Corey T McMillan; C Dirk Keene; Caitlin S Latimer; Thomas J Montine; Gabor G Kovacs; Mirjam I Lutz; Peter Fischer; Richard J Perrin; Nigel J Cairns; Erin E Franklin; Herbert T Cohen; Towfique Raj; Inma Cobos; Bess Frost; Alison Goate; Charles L White Iii; John F Crary
Journal:  Acta Neuropathol       Date:  2021-11-01       Impact factor: 15.887

Review 7.  Neuropathology of Alzheimer's Disease.

Authors:  Jorge A Trejo-Lopez; Anthony T Yachnis; Stefan Prokop
Journal:  Neurotherapeutics       Date:  2021-11-02       Impact factor: 6.088

8.  Asymmetry of Hippocampal Tau Pathology in Primary Age-Related Tauopathy and Alzheimer Disease.

Authors:  Jamie M Walker; Yelena Fudym; Kurt Farrell; Megan A Iida; Kevin F Bieniek; Sudha Seshadri; Charles L White; John F Crary; Timothy E Richardson
Journal:  J Neuropathol Exp Neurol       Date:  2021-04-16       Impact factor: 3.685

9.  Tau isoforms are differentially expressed across the hippocampus in chronic traumatic encephalopathy and Alzheimer's disease.

Authors:  Jonathan D Cherry; Camille D Esnault; Zachary H Baucom; Yorghos Tripodis; Bertrand R Huber; Victor E Alvarez; Thor D Stein; Dennis W Dickson; Ann C McKee
Journal:  Acta Neuropathol Commun       Date:  2021-05-12       Impact factor: 7.578

10.  Medial Temporal Lobe Involvement in Human Prion Diseases: Implications for the Study of Focal Non Prion Neurodegenerative Pathology.

Authors:  Alberto Rábano; Carmen Guerrero Márquez; Ramón A Juste; María V Geijo; Miguel Calero
Journal:  Biomolecules       Date:  2021-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.